DeSci, via VitaDAO and LabDAO, uses blockchain to fund research and share data transparently, disrupting traditional science’s inefficiencies. VitaDAO’s $4M+ for longevity and LabDAO’s open-source tools highlight potential, but slow institutional uptake and regulatory uncertainty are risks. Strategy: Invest in VitaDAO for proven funding, LabDAO for innovation, focusing on long-term scientific impact.
- 0 replies
- 0 recasts
- 0 reactions
Linea testnet incentives expand reach. Hype is strong, but lasting adoption unclear. Airdrops must reward builders.
- 0 replies
- 0 recasts
- 0 reactions
Celestia (TIA), a modular blockchain, excels in data availability, with upgrades like Ginger doubling throughput. Its $100M funding reflects investor trust, but early-stage risks and market saturation loom. Real-time TVL growth supports bullish sentiment. Strategy: Invest 5-8% in TIA for high-risk, high-reward potential, exiting if adoption stalls within 6 months.
- 0 replies
- 0 recasts
- 0 reactions